Literature DB >> 23122672

Postural tachycardia syndrome: a heterogeneous and multifactorial disorder.

Eduardo E Benarroch1.   

Abstract

Postural tachycardia syndrome (POTS) is defined by a heart rate increment of 30 beats/min or more within 10 minutes of standing or head-up tilt in the absence of orthostatic hypotension; the standing heart rate is often 120 beats/min or higher. POTS manifests with symptoms of cerebral hypoperfusion and excessive sympathoexcitation. The pathophysiology of POTS is heterogeneous and includes impaired sympathetically mediated vasoconstriction, excessive sympathetic drive, volume dysregulation, and deconditioning. POTS is frequently included in the differential diagnosis of chronic unexplained symptoms, such as inappropriate sinus tachycardia, chronic fatigue, chronic dizziness, or unexplained spells in otherwise healthy young individuals. Many patients with POTS also report symptoms not attributable to orthostatic intolerance, including those of functional gastrointestinal or bladder disorders, chronic headache, fibromyalgia, and sleep disturbances. In many of these cases, cognitive and behavioral factors, somatic hypervigilance associated with anxiety, depression, and behavioral amplification contribute to symptom chronicity. The aims of evaluation in patients with POTS are to exclude cardiac causes of inappropriate tachycardia; elucidate, if possible, the most likely pathophysiologic basis of postural intolerance; assess for the presence of treatable autonomic neuropathies; exclude endocrine causes of a hyperadrenergic state; evaluate for cardiovascular deconditioning; and determine the contribution of emotional and behavioral factors to the patient's symptoms. Management of POTS includes avoidance of precipitating factors, volume expansion, physical countermaneuvers, exercise training, pharmacotherapy (fludrocortisone, midodrine, β-blockers, and/or pyridostigmine), and behavioral-cognitive therapy. A literature search of PubMed for articles published from January 1, 1990, to June 15, 2012, was performed using the following terms (or combination of terms): POTS; postural tachycardia syndrome, orthostatic; orthostatic; syncope; sympathetic; baroreceptors; vestibulosympathetic; hypovolemia; visceral pain; chronic fatigue; deconditioning; headache; Chiari malformation; Ehlers-Danlos; emotion; amygdala; insula; anterior cingulate; periaqueductal gray; fludrocortisone; midodrine; propranolol; β-adrenergic; and pyridostigmine. Studies were limited to those published in English. Other articles were identified from bibliographies of the retrieved articles.
Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23122672      PMCID: PMC3547546          DOI: 10.1016/j.mayocp.2012.08.013

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  96 in total

1.  Regulation of muscle sympathetic nerve activity after bed rest deconditioning.

Authors:  J A Pawelczyk; J H Zuckerman; C G Blomqvist; B D Levine
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-05       Impact factor: 4.733

2.  Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects.

Authors:  Julian M Stewart
Journal:  Circulation       Date:  2002-05-14       Impact factor: 29.690

Review 3.  Psychopathology and the human connectome: toward a transdiagnostic model of risk for mental illness.

Authors:  Joshua W Buckholtz; Andreas Meyer-Lindenberg
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

Review 4.  A review of postural orthostatic tachycardia syndrome.

Authors:  Sheila Carew; Margaret O Connor; John Cooke; Richard Conway; Christine Sheehy; Aine Costelloe; Declan Lyons
Journal:  Europace       Date:  2009-01       Impact factor: 5.214

Review 5.  Management and pathophysiology of functional gastrointestinal disorders.

Authors:  Shin Fukudo; Hiroyuki Kuwano; Hiroto Miwa
Journal:  Digestion       Date:  2012-01-19       Impact factor: 3.216

Review 6.  [Anti-VGKC antibody-associated limbic encephalitis/Morvan syndrome].

Authors:  Tamako Misawa; Hidehiro Mizusawa
Journal:  Brain Nerve       Date:  2010-04

7.  Autonomic dysfunction presenting as postural tachycardia syndrome following traumatic brain injury.

Authors:  Khalil Kanjwal; Beverly Karabin; Yousuf Kanjwal; Blair P Grubb
Journal:  Cardiol J       Date:  2010       Impact factor: 2.737

8.  Deconditioning in patients with orthostatic intolerance.

Authors:  Ajay Parsaik; Thomas G Allison; Wolfgang Singer; David M Sletten; Michael J Joyner; Eduardo E Benarroch; Phillip A Low; Paola Sandroni
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

Review 9.  Central nervous system reorganization in a variety of chronic pain states: a review.

Authors:  Douglas E Henry; Anthony E Chiodo; Weibin Yang
Journal:  PM R       Date:  2011-12       Impact factor: 2.298

Review 10.  The protean manifestations of pheochromocytoma.

Authors:  W M Manger
Journal:  Horm Metab Res       Date:  2009-02-25       Impact factor: 2.936

View more
  102 in total

1.  Intravenous Hydration for Management of Medication-Resistant Orthostatic Intolerance in the Adolescent and Young Adult.

Authors:  Jeffrey P Moak; Derek Leong; Robin Fabian; Vicki Freedenberg; Elizabeth Jarosz; Carol Toney; Sridhar Hanumanthaiah; Anil Darbari
Journal:  Pediatr Cardiol       Date:  2015-10-07       Impact factor: 1.655

2.  Emerging subspecialties in neurology: autonomic disorders.

Authors:  Jose-Alberto Palma; Glen A Cook; Mitchell G Miglis; Adam Loavenbruck
Journal:  Neurology       Date:  2015-03-10       Impact factor: 9.910

3.  Postural orthostatic tachycardia syndrome (POTS): association with Ehlers-Danlos syndrome and orthopaedic considerations.

Authors:  Emmanouil Grigoriou; Jeffrey R Boris; John P Dormans
Journal:  Clin Orthop Relat Res       Date:  2014-08-26       Impact factor: 4.176

4.  What is brain fog? An evaluation of the symptom in postural tachycardia syndrome.

Authors:  Amanda J Ross; Marvin S Medow; Peter C Rowe; Julian M Stewart
Journal:  Clin Auton Res       Date:  2013-09-03       Impact factor: 4.435

5.  Heart rate, conduction and ultrasound abnormalities in adults with joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type.

Authors:  Filippo Camerota; Marco Castori; Claudia Celletti; Marco Colotto; Silvia Amato; Alessandra Colella; Mario Curione; Chiara Danese
Journal:  Clin Rheumatol       Date:  2014-04-22       Impact factor: 2.980

6.  2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.

Authors:  Robert S Sheldon; Blair P Grubb; Brian Olshansky; Win-Kuang Shen; Hugh Calkins; Michele Brignole; Satish R Raj; Andrew D Krahn; Carlos A Morillo; Julian M Stewart; Richard Sutton; Paola Sandroni; Karen J Friday; Denise Tessariol Hachul; Mitchell I Cohen; Dennis H Lau; Kenneth A Mayuga; Jeffrey P Moak; Roopinder K Sandhu; Khalil Kanjwal
Journal:  Heart Rhythm       Date:  2015-05-14       Impact factor: 6.343

Review 7.  Arterial flow waveforms, vascular tone, and chronic fatigue: a case report.

Authors:  M Tracy Zundel; Matthew Pattyn; Thomas C Chelimsky; Matthias L Riess
Journal:  Auton Neurosci       Date:  2015-03-24       Impact factor: 3.145

Review 8.  Fibromyalgia and small fiber neuropathy: the plot thickens!

Authors:  Manuel Martínez-Lavín
Journal:  Clin Rheumatol       Date:  2018-09-20       Impact factor: 2.980

9.  Gastrointestinal symptoms in postural tachycardia syndrome: a systematic review.

Authors:  Shahram E Mehr; Adrian Barbul; Cyndya A Shibao
Journal:  Clin Auton Res       Date:  2018-03-16       Impact factor: 4.435

10.  Disturbances of gastrointestinal transit and autonomic functions in postural orthostatic tachycardia syndrome.

Authors:  A Loavenbruck; J Iturrino; W Singer; D M Sletten; P A Low; A R Zinsmeister; A E Bharucha
Journal:  Neurogastroenterol Motil       Date:  2014-12-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.